555 A high-throughput in situ screen to identify synergistic combinations of immune-oncology drugs with targeted and cytotoxic agents in a patient-derived humanized mouse model of renal cancer

• Julia Schüler,
• Oliver Jonas,
• Eva Oswald,
• Kanstantsin Lashuk,
• Sebastian Ahn

Affiliations

Julia Schüler

Aff667 Oncotest GmbH Freiburg Baden-Wurttemberg Germany

Oliver Jonas

1Harvard Medical School, Boston, MA, USA

Eva Oswald

2Charles River Research Services Germany, Freiburg, Germany

Kanstantsin Lashuk

2Charles River Research Services Germany, Freiburg, Germany

Sebastian Ahn

1Harvard Medical School, Boston, MA, USA